When Dianabol was introduced in 2017, it was hailed as a major breakthrough for the bodybuilding community.
However, there have been numerous controversies surrounding the treatment and the safety of its use.
Today, the company is still on the brink of a major regulatory response after a number of serious accidents and fatalities in the US and Europe.
In this episode, I talk to Dianabol’s CEO, Mark Miller, about the company’s status, how it’s evolved over the past few years, and what to expect in the future.
I also discuss the recent controversy surrounding the brand’s use of a new, potentially more dangerous and addictive form of a stimulant called “Dianabol.”
Related: What to Know About Bodybuilding Medicine From a Medical Perspective, Part 2: What the FDA and FDA Commissioner Scott Gottlieb Should Know About the FDA Response to the Deadly Accident